Prospective Randomized Control Pilot Study to Compare the Role of Injection Cerebrolysin in Operated cases of Degenerative Cervical Myelopathy.

Sharma A, Marathe N, Aggarwal R, Singh V, Shakya A, Kamble P, Jaiswal A, Mangale N, Rocos B

Spine1 Jan 2022Cited by 7 (Europe PMC)

PMID34889883DOI10.1097/brs.0000000000004131PepBankPUB-34889883

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, mJOA improvement did not differ between Cerebrolysin and placebo.
In plain wordsIn operated DCM patients, functional improvement did not differ between Cerebrolysin and placebo.
Peptide
Cerebrolysin
Outcome
No significant changemJOA improvement
Study
n = 60
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Source sentences
Summary
In comparing the two groups, there was no difference in improvement of mJOA and VAS scores.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988301
02HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, VAS improvement did not differ between Cerebrolysin and placebo.
In plain wordsIn operated DCM patients, pain improvement did not differ between Cerebrolysin and placebo.
Peptide
Cerebrolysin
Outcome
No significant changeVAS improvement
Study
n = 60
Comparator
Placebo
Outcome group
Pain · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Source sentences
Summary
In comparing the two groups, there was no difference in improvement of mJOA and VAS scores.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988302
03HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, mJOA scores improved in both Cerebrolysin and placebo groups at all reported follow-ups.
In plain wordsIn operated DCM patients, functional scores improved in both Cerebrolysin and placebo groups.
Peptide
Cerebrolysin
Outcome
IncreasemJOA change over follow-up
Study
n = 60
Comparator
Baseline
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Measurements
p value for mJOA improvement
< 0.01
within-group improvement in both Cerebrolysin and placebo groups at 3 weeks, 3 months, 6 months, and 1 year
Source sentences
Summary
Both groups showed significant improvement in both mJOA and VAS scores at 3weeks, 3 months, 6 months and 1-year follow-up (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988303
04HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, VAS scores improved in both Cerebrolysin and placebo groups at all reported follow-ups.
In plain wordsIn operated DCM patients, pain scores improved in both Cerebrolysin and placebo groups.
Peptide
Cerebrolysin
Outcome
DecreaseVAS change over follow-up
Study
n = 60
Comparator
Baseline
Outcome group
Pain · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Measurements
p value for VAS improvement
< 0.01
within-group improvement in both Cerebrolysin and placebo groups at 3 weeks, 3 months, 6 months, and 1 year
Source sentences
Summary
Both groups showed significant improvement in both mJOA and VAS scores at 3weeks, 3 months, 6 months and 1-year follow-up (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988304
05HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, Cerebrolysin improved hand function at 1 year compared with placebo.
In plain wordsIn operated DCM patients, Cerebrolysin improved hand function at 1 year compared with placebo.
Peptide
Cerebrolysin
Outcome
IncreaseHand function
Study
n = 60
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Source sentences
Summary
However, cerebrolysin group showed significant improvement in hand function at 1 year compared to the placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988305
06HumanRandomized controlled trialEfficacy outcome
In operated DCM patients, complete recovery occurred in 66.7% with Cerebrolysin versus 56.7% with placebo, without statistical significance.
In plain wordsIn operated DCM patients, complete recovery did not differ significantly between Cerebrolysin and placebo.
Peptide
Cerebrolysin
Outcome
No significant changeComplete neurological recovery
Study
n = 60
Comparator
Placebo
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Measurements
Patients with complete neurological recovery
66.7%
Cerebrolysin
Patients with complete neurological recovery
56.7%
placebo
Source sentences
Summary
Postoperative neurological recovery was better in the cerebrolysin group with 66.7% patients showing complete neurological recovery compared to 56.7% for placebo, but this was statistically insignificant.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988306
07HumanRandomized controlled trialSafety outcome
In operated DCM patients, two Cerebrolysin patients developed headache that resolved without intervention.
In plain wordsIn operated DCM patients, two Cerebrolysin patients developed headache that resolved without intervention.
Peptide
Cerebrolysin
Outcome
Not applicableHeadache
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Measurements
Patients with headache
2 patients
Cerebrolysin group
Source sentences
Summary
Two patients developed headache and one patient complained of dizziness in the cerebrolysin group, but these resolved without any intervention.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988307
08HumanRandomized controlled trialSafety outcome
In operated DCM patients, one Cerebrolysin patient developed dizziness that resolved without intervention.
In plain wordsIn operated DCM patients, one Cerebrolysin patient developed dizziness that resolved without intervention.
Peptide
Cerebrolysin
Outcome
Not applicableDizziness
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
5 mL diluted in 100 mL normal saline over 30 minutes, once a day · injection · 21 daysAs given in this study (human).
Measurements
Patients with dizziness
1 patients
Cerebrolysin group
Source sentences
Summary
Two patients developed headache and one patient complained of dizziness in the cerebrolysin group, but these resolved without any intervention.
3 context sentences(design, population, supporting numbers)
Summary · context
Sixty operated cases of DCM were randomly divided into 2 groups.
Summary · context
The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively.
Summary · context
The second group was given placebo.
Report a problemFND-3488988308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.